SeaStar Medical Holding Corporation (ICU) Research
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
Market snapshot
- Symbol
- ICU
- Price
- $3.12
- Day change
- +1.96%
- Market cap
- $8.9M
- P/E ratio
- -10.27x
- 52-week range
- 2.07-12.5
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $8.00
Recent news
- This ICU Medical Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Peer companies
Recent insider activity
- Van Heel Kenneth — A-Award (3000 shares) on 2026-02-06
- Neuman John — A-Award (3000 shares) on 2026-02-06
- Vincent Bernadette N — A-Award (3000 shares) on 2026-02-06
- Baird Jennifer A — A-Award (3000 shares) on 2026-02-06
- Towne Bradford K — A-Award (7500 shares) on 2026-02-06
Open SeaStar Medical Holding Corporation (ICU) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.